Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Leuk Res, 2011/4;35(4):465-71.
Giachelia M[1], D'Alò F, Fabiani E, Saulnier N, Di Ruscio A, Guidi F, Hohaus S, Voso MT, Leone G
Affiliations
PMID: 20869114DOI: 10.1016/j.leukres.2010.07.022
Impact factor: 3.715
Abstract
Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.
MeSH terms
Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antimetabolites, Antineoplastic; Azacitidine; Cluster Analysis; DNA Methylation; Decitabine; Female; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Integrin beta1; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Young Adult
More resources
EndNote: Download